Pegaptanib intravitreal injection
What is this medicine?
PEGAPTANIB (peg AP ta nib) is a drug that is injected into the eye. It is used to treat macular degeneration. This treatment results in a slowing of the disease and helps to maintain vision. It is not a cure.
How should I use this medicine?
This medicine is injected into the eye by an eye doctor who specializes in this treatment. The eye doctor will numb your eye and give you antibiotic eye drops. The injection is usually given every 6 weeks.
Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
changes in vision
sensitivity of the eyes to light
swelling or redness of the eye or eyelid
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
temporary blurred vision or eye irritation
What may interact with this medicine?
Interactions are not expected.
Do not use any other eye products without asking your doctor or health care professional.
What if I miss a dose?
It is important not to miss your dose. Call your doctor or health care professional if you are unable to keep an appointment.
Where should I keep my medicine?
This drug is given in a hospital or clinic and will not be stored at home.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
cataracts or glaucoma
an unusual or allergic reaction to Pegaptanib, other medicines, foods, dyes, or preservatives
pregnant or trying to get pregnant
What should I watch for while using this medicine?
Your eye doctor will monitor the effects of this medicine closely. You may need to return to the office between 2 and 7 days after the treatment for a check on your condition and your response to the treatment.
September 30, 2017